ライフサイエンスコーパス: cardioverter

1 of cardiac resynchronization therapy with a cardioverter defibrillator (CRT-D) on the effect of ICD

2 ften avoided after receipt of an implantable cardioverter defibrillator (ICD) because of fears that e

3 showed a survival benefit of the implantable cardioverter defibrillator (ICD) in males with arrhythmo

4 se of CRT in combination with an implantable cardioverter defibrillator (ICD) in patients who are eli

5 The implantable-cardioverter defibrillator (ICD) lead is the most vulner

6 iovascular Data Registry (NCDR), implantable cardioverter defibrillator (ICD) registry between 2006 a

7 netic resonance (MR)-conditional implantable cardioverter defibrillator (ICD) systems have become ava

8 To our knowledge, whether implantable cardioverter defibrillator (ICD) therapy improves surviv

9 neity of LGE predict appropriate implantable cardioverter defibrillator (ICD) therapy in ischemic car

10 icant reduction in inappropriate implantable cardioverter defibrillator (ICD) therapy in patients pro

11 ients randomized to CRT-D versus implantable cardioverter defibrillator (ICD) were compared within th

12 ith defibrillator (CRT-D) versus implantable cardioverter defibrillator (ICD), and outcomes.

13 rly adoption of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the United States

14 a on the safety and efficacy of the wearable cardioverter defibrillator (WCD) in a real-world setting

15 ar fibrillation; and n=8 without implantable cardioverter defibrillator although with symptomatic com

16 rms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopat

17 The implantable cardioverter defibrillator appropriate intervention rate

18 iate analysis showed that in the implantable cardioverter defibrillator arm, each 10-mm Hg decrement

19 ggested for effect modification (implantable cardioverter defibrillator at baseline, left ventricular

20 nd CRT with defibrillator versus implantable cardioverter defibrillator benefit was assessed in multi

21 important criterion to determine implantable cardioverter defibrillator candidacy.

22 requent reason not to implant an implantable cardioverter defibrillator following WCD use was improve

23 ardiac resynchronization therapy implantable cardioverter defibrillator for the treatment of heart fa

24 nificant complication related to implantable cardioverter defibrillator implantation in comparison wi

25 who are the best candidates for implantable cardioverter defibrillator implantation is one of the mo

26 vation require further study but implantable cardioverter defibrillator implantation should not be gu

27 referred for primary prevention implantable cardioverter defibrillator implantation were prospective

28 linical data, arrhythmia events, implantable cardioverter defibrillator implantation, and improvement

29 ncomplete revascularization, and implantable cardioverter defibrillator implantation.

30 nd pediatric patients undergoing implantable cardioverter defibrillator implantation.

31 udden death who may benefit from implantable cardioverter defibrillator implantation.

32 ave a preexisting indication for implantable cardioverter defibrillator implantation.

33 nes only recommend the use of an implantable cardioverter defibrillator in patients with dilated card

34 20 ms) receiving either CRT-D or implantable cardioverter defibrillator in subgroups according to QRS

35 Implantable cardioverter defibrillator indications for patients with

36 complications and inappropriate implantable cardioverter defibrillator interventions.

37 Implantable cardioverter defibrillator is the only proven lifesaving

38 with persistent AF, dual-chamber implantable cardioverter defibrillator or cardiac resynchronization

39 tery bypass grafts, 2 epicardial implantable cardioverter defibrillator placement, 5 valve surgery, 2

40 results in approximately 130 000 implantable cardioverter defibrillator placements at a cost of >$3 b

41 In this article, we report implantable cardioverter defibrillator procedures (April 2010 to Dec

42 Medicare patients from the Implantable Cardioverter Defibrillator Registry (January 1, 2005, th

43 e competing risks of appropriate implantable cardioverter defibrillator shock versus mortality.

44 the ventricular rate out of the implantable cardioverter defibrillator shock zone.

45 with previous cardiac arrest and implantable cardioverter defibrillator shocks for ventricular fibril

46 e risks of death from any cause, implantable cardioverter defibrillator shocks, and syncope.

47 symptoms and reduces appropriate implantable cardioverter defibrillator shocks.

48 ring AF to prevent inappropriate implantable cardioverter defibrillator shocks.

49 but not sudden cardiac death or implantable cardioverter defibrillator shocks.

50 risk of receiving inappropriate implantable cardioverter defibrillator shocks.

51 Patients who receive implantable cardioverter defibrillator therapies are at higher risk

52 n cardiac arrest, 40 appropriate implantable cardioverter defibrillator therapies).

53 e studied (6 month preprocedural implantable cardioverter defibrillator therapies: median 19 ATP even

54 her risk of mortality or HF with implantable cardioverter defibrillator therapy alone.

55 e less likely to be referred for implantable cardioverter defibrillator therapy despite current guide

56 of patients received appropriate implantable cardioverter defibrillator therapy during medium-term fo

57 of end point events by CRT-D to implantable cardioverter defibrillator therapy in the PR subgroups.

58 n cardiac death, and appropriate implantable cardioverter defibrillator therapy was noted.

59 ital cardiac arrest, appropriate implantable cardioverter defibrillator therapy, and sudden cardiac d

60 patients with heart failure for implantable cardioverter defibrillator therapy.

61 teraction P<0.001) compared with implantable cardioverter defibrillator therapy.

62 .13-0.57; P<0.001) compared with implantable cardioverter defibrillator therapy.

63 nal cardioversion or appropriate implantable cardioverter defibrillator therapy.

64 in the selection of patients for implantable cardioverter defibrillator therapy.

65 y gain longevity from successful implantable cardioverter defibrillator therapy.

66 en cardiac arrest or appropriate implantable cardioverter defibrillator therapy.

67 An intracardiac cardioverter defibrillator was implanted in 31 patients,

68 An implantable cardioverter defibrillator was implanted in 61 (16.8%) p

69 ower mortality with CRT-D versus implantable cardioverter defibrillator was less pronounced (absolute

70 Treatment with implantable cardioverter defibrillator was rare (3%) and resulted in

71 Data from 836 patients with implantable cardioverter defibrillator without or with cardiac resyn

72 ]), and survivors more often had implantable cardioverter defibrillator's implanted (OR, 2.1 [1.2-3.6

73 oronary artery disease severity, implantable cardioverter defibrillator, and incomplete revasculariza

74 ents who are not eligible for an implantable cardioverter defibrillator, and suggests that the WCD ca

75 action 35% or less, an automatic implantable cardioverter defibrillator, and who were ineligible for

76 ntitachycardia pacing from their implantable cardioverter defibrillator, or both.

77 referred for primary prevention implantable cardioverter defibrillator, we developed dual risk strat

78 assess the clinical outcome of all internal cardioverter defibrillator-only patients (n=714) with a

79 S-LVRR occurred in 25% of internal cardioverter defibrillator-only patients.

80 up) among 612 patients treated with internal cardioverter defibrillator-only therapy in Multicenter A

81 the risk of HF or death only among internal cardioverter defibrillator-treated patients with a low (

82 ely to benefit from prophylactic implantable cardioverter defibrillator.

83 nts (42%) were implanted with an implantable cardioverter defibrillator.

84 e-saving preventive therapy, the implantable cardioverter defibrillator.

85 aker, and 1 has a single chamber implantable cardioverter defibrillator.

86 ociation HF class, and implanted implantable cardioverter defibrillator/cardiac resynchronization the

87 among index-patients without an implantable cardioverter-defibrillator (10/63, 16% versus 2/335, 0.6

88 who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was not considered

89 ath risk than those receiving an implantable cardioverter-defibrillator (absolute difference, 11%; ha

90 biventricular pacemaker with an implantable cardioverter-defibrillator (CRT-D).

91 illator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) alone are unclear.

92 ith defibrillator (CRT-D) versus implantable cardioverter-defibrillator (ICD) alone in CRT-eligible p

93 es with the benefits of CRT over implantable cardioverter-defibrillator (ICD) alone.

94 ligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less likely than me

95 reassessed 40 days after MI for implantable cardioverter-defibrillator (ICD) candidacy.

96 Guidelines recommend that implantable cardioverter-defibrillator (ICD) candidates have an esti

97 heter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt treatment of

98 The subcutaneous implantable cardioverter-defibrillator (ICD) has emerged as a novel

99 edictive of an inadequate DSM at implantable cardioverter-defibrillator (ICD) implantation and to exa

100 SCD may be prevented by implantable cardioverter-defibrillator (ICD) implantation, but patie

101 hat primary prevention use of an implantable cardioverter-defibrillator (ICD) improves survival in pa

102 The benefit of an implantable cardioverter-defibrillator (ICD) in patients with sympto

103 have established the role of the implantable cardioverter-defibrillator (ICD) in the treatment and pr

104 Implantable cardioverter-defibrillator (ICD) indications for primary

105 The rate of implantable cardioverter-defibrillator (ICD) infections has been inc

106 of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent despite ant

107 The implantable cardioverter-defibrillator (ICD) is the standard therapy

108 For the former, an implantable cardioverter-defibrillator (ICD) is typically required d

109 with an unused or malfunctioning implantable cardioverter-defibrillator (ICD) lead may have the lead

110 t of lead diameter and design on implantable cardioverter-defibrillator (ICD) lead survival in childr

111 ations in patients randomized to implantable cardioverter-defibrillator (ICD) or ICD-CRT in the Resyn

112 ations for CRT-D were matched to implantable cardioverter-defibrillator (ICD) patients without CRT de

113 ong-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement are poorly de

114 ization after primary prevention implantable cardioverter-defibrillator (ICD) placement is uncertain.

115 mended before primary prevention implantable cardioverter-defibrillator (ICD) placement.

116 ythmias (VAs) and should undergo implantable cardioverter-defibrillator (ICD) placement.

117 Implantable cardioverter-defibrillator (ICD) recipients require clos

118 onary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries of the NCDR.

119 l Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator (ICD) Registry hospitalized p

120 en shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in small series

121 3 to 6 months after appropriate implantable cardioverter-defibrillator (ICD) shocks, contemporary da

122 patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "non-MRI-condi

123 ynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) therapies in patients w

124 diac resynchronization (CRT) and implantable cardioverter-defibrillator (ICD) therapies in patients w

125 a long detection window reduces implantable cardioverter-defibrillator (ICD) therapy in primary prev

126 Trials comparing implantable cardioverter-defibrillator (ICD) therapy with cardiac re

127 onstrated improved survival with implantable cardioverter-defibrillator (ICD) therapy.

128 py with defibrillator (CRT-D) to implantable cardioverter-defibrillator (ICD) treatment in mildly sym

129 hy (PPCM) and to record rates of implantable cardioverter-defibrillator (ICD) use.

130 ces that include the transvenous implantable cardioverter-defibrillator (ICD) with or without cardiac

131 into three groups: HF without an implantable cardioverter-defibrillator (ICD), HF with an ICD without

132 ic external defibrillator (AED), implantable cardioverter-defibrillator (ICD), or wearable cardiovert

133 uld predict arrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible cardiomyopathy

134 ict the survival benefit with an implantable cardioverter-defibrillator (ICD).

135 welve children (30%) received an implantable cardioverter-defibrillator (ICD).

136 that was induced by means of an implantable cardioverter-defibrillator (ICD).

137 rmanent pacemaker rather than an implantable cardioverter-defibrillator (odds ratio, 3.90; 95% confid

138 The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the first implanta

139 it a challenge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening.

140 mercially available subcutaneous implantable cardioverter-defibrillator (S-ICD) uses a completely sub

141 The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defi

142 This study evaluated the wearable cardioverter-defibrillator (WCD) for use and effectivene

143 The wearable cardioverter-defibrillator (WCD) has emerged as a means

144 ardioverter-defibrillator (ICD), or wearable cardioverter-defibrillator (WCD).

145 ased risk with CRT-D relative to implantable cardioverter-defibrillator -only.

146 rimary prevention defibrillator (implantable cardioverter-defibrillator [ICD]) population.

147 ac arrest survivors treated with implantable cardioverter-defibrillator alone but did not recur on qu

148 chronization therapy (CRT-D) to an implanted cardioverter-defibrillator alters the risk of atrial fib

149 216 (45.3%) patients randomized to implanted cardioverter-defibrillator and 249 (50.3%) randomized to

150 56% among patients randomized to implantable cardioverter-defibrillator and CRT with defibrillator (C

151 treatment options including the implantable cardioverter-defibrillator and heart transplantation (HT

152 We excluded patients with prior implantable cardioverter-defibrillator and those randomized only to

153 isions about the placement of an implantable cardioverter-defibrillator are based on an estimate of a

154 sudden death prevention with an implantable cardioverter-defibrillator are identified.

155 er increase in RWT compared with implantable cardioverter-defibrillator at 12 months (4.6 +/- 6.8% vs

156 Patients who had an implantable cardioverter-defibrillator at the time of trial enrollme

157 Although an implantable cardioverter-defibrillator can save lives in individuals

158 tment 18 experienced appropriate implantable cardioverter-defibrillator discharges, 2 underwent heart

159 ortality, composite end point of implantable cardioverter-defibrillator efficacy (arrhythmic deaths a

160 Patients with implantable cardioverter-defibrillator explantation had an incidence

161 nt of cardiac death, appropriate implantable cardioverter-defibrillator firing, resuscitated cardiac

162 and implantation of an automatic implantable cardioverter-defibrillator for prevention of sudden deat

163 lecting patients with DCM for an implantable cardioverter-defibrillator for primary prevention purpos

164 and the life-saving role of the implantable cardioverter-defibrillator highlight the importance of r

165 agnetic resonance imaging before implantable cardioverter-defibrillator implantation for primary and

166 t for the decision making before implantable cardioverter-defibrillator implantation for the primary

167 thmias, sudden cardiac death, or implantable cardioverter-defibrillator implantation in a cohort of 2

168 , implying that further delay of implantable cardioverter-defibrillator implantation may not be warra

169 strategy to confine prophylactic implantable cardioverter-defibrillator implantation to patients with

170 us no-DFT testing at the time of implantable cardioverter-defibrillator implantation was performed to

171 is no survival benefit of early implantable cardioverter-defibrillator implantation, and the optimal

172 index-patients was modulated by implantable cardioverter-defibrillator implantation, but not by muta

173 ant potential to guide patient selection for cardioverter-defibrillator implantation.

174 lection of patients with DCM for implantable cardioverter-defibrillator implantation.

175 rect impact on the indication of implantable cardioverter-defibrillator implantation.

176 creased risk of sudden cardiac death undergo cardioverter-defibrillator implantation; in patients wit

177 can usually be averted by implantation of a cardioverter-defibrillator in appropriate high-risk pati

178 uclear procedures, and pacemaker/implantable cardioverter-defibrillator insertion and repair.

179 (1.0 to 2.4 per 1000), pacemaker/implantable cardioverter-defibrillator insertions (1.6 to 4.4 per 10

180 er high-risk patients (13%) with implantable cardioverter-defibrillator interventions for ventricular

181 The implantable cardioverter-defibrillator is associated with changes in

182 or patients at increased risk an implantable cardioverter-defibrillator is recommended, it is widely

183 ng-term management of indwelling implantable cardioverter-defibrillator leads in young patients (>40-

184 implantation of the subcutaneous implantable cardioverter-defibrillator may offer procedural and cosm

185 ation or death with CRT-D versus implantable cardioverter-defibrillator only therapy, whereas the eff

186 t may warrant implantation of an implantable cardioverter-defibrillator or cardiac resynchronization

187 Patients with a prior implantable cardioverter-defibrillator or sustained ventricular arrh

188 gate the impact of an additional implantable cardioverter-defibrillator over CRT, according to underl

189 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients with recurrences was

190 uartile range of 540) days after implantable cardioverter-defibrillator placement.

191 al Cardiovascular Data Registry, implantable cardioverter-defibrillator registry between 2006 and 200

192 luding death, HT, or appropriate implantable cardioverter-defibrillator shock were assessed in 71 con

193 After implantable cardioverter-defibrillator shock, related HCU was common

194 quency catheter ablation reduced implantable cardioverter-defibrillator shocks and VT episodes and im

195 the proportion of patients with implantable cardioverter-defibrillator shocks decreased from 81.2% t

196 Appropriate implantable cardioverter-defibrillator shocks occurred in 11 of 34 i

197 cular tachycardia requiring >/=2 implantable cardioverter-defibrillator shocks occurred in 13 patient

198 Implantable cardioverter-defibrillator shocks seem to trigger a casc

199 ricular fibrillation-terminating implantable cardioverter-defibrillator shocks, and sudden cardiac de

200 to rates observed in transvenous implantable cardioverter-defibrillator studies.

201 d a legacy pacemaker or a legacy implantable cardioverter-defibrillator system.

202 have an attenuated benefit from implantable cardioverter-defibrillator therapy (older adults with mu

203 Implantable cardioverter-defibrillator therapy improves survival in

204 it is also well recognized that implantable cardioverter-defibrillator therapy is associated with bo

205 allenging because the benefit of implantable cardioverter-defibrillator therapy may not be uniform, p

206 Appropriate implantable cardioverter-defibrillator therapy was delivered in 23 p

207 om additional primary prevention implantable cardioverter-defibrillator therapy, as opposed to those

208 composite of SCD and appropriate implantable cardioverter-defibrillator therapy, identical to the HCM

209 ry combined outcome (appropriate implantable cardioverter-defibrillator therapy, survived cardiac arr

210 evaluated for primary prevention implantable cardioverter-defibrillator therapy.

211 Implantable cardioverter-defibrillator therapy.

212 , and 6 (23%) were suggested for implantable cardioverter-defibrillator therapy.

213 linical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a baseline exercise

214 of SCD and a low rate of primary implantable cardioverter-defibrillator utilization in patients with

215 ate (4.0%) of primary prevention implantable cardioverter-defibrillator utilization.

216 n extent that the indication for implantable cardioverter-defibrillator was no longer present.

217 an age 39 years (30.3-42.3) with implantable cardioverter-defibrillator were enrolled.

218 le for a late primary prevention implantable cardioverter-defibrillator with LVEF </=30% or </=35% wi

219 h defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator) was associated with a greate

220 total of 81 patients received an implantable cardioverter-defibrillator, 34 were successfully defibri

221 sease, cardiac resynchronization implantable cardioverter-defibrillator, and VT storm despite greater

222 dia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new

223 atient, with prior biventricular implantable cardioverter-defibrillator, diastolic activity was recor

224 (29%) of 78 IVF patients with an implantable cardioverter-defibrillator, with a median of 3 appropria

225 e subcutaneous ICD (S-ICD), and the wearable cardioverter-defibrillator.

226 s a class I indication for implantation of a cardioverter-defibrillator.

227 ely managed long-term without an implantable cardioverter-defibrillator.

228 sis without the protection of an implantable cardioverter-defibrillator.

229 t techniques of the subcutaneous implantable cardioverter-defibrillator.

230 cient to justify placement of an implantable cardioverter-defibrillator.

231 onresynchronization defibrillator (implanted cardioverter-defibrillator; n=477) within the predefined

232 mote patient monitoring (RPM) of implantable cardioverter defibrillators (ICD) and all-cause mortalit

233 in patients with pacemakers and implantable cardioverter defibrillators (ICDs) and evaluate associat

234 patients who are candidates for implantable cardioverter defibrillators (ICDs) are not referred for

235 Clinical trials of implantable cardioverter defibrillators (ICDs) for primary preventio

236 have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary preventio

237 Primary prevention implantable cardioverter defibrillators (ICDs) reduce all-cause mort

238 risk, prophylactic insertion of implantable cardioverter defibrillators (ICDs) reduces mortality.

239 Previous systematic reviews of implantable cardioverter defibrillators (ICDs) used for primary prev

240 Implantable cardioverter defibrillators (ICDs) used to prevent sudde

241 as evaluated in 12 patients with implantable cardioverter defibrillators (ICDs) who were referred for

242 roup comprised 160 patients with implantable cardioverter defibrillators (ICDs), of whom 94 patients

243 e at the time of implantation of implantable cardioverter defibrillators (ICDs).

244 ospective Observational Study of Implantable Cardioverter Defibrillators (PROSe-ICD) enrolled 1189 pa

245 he recent advent of subcutaneous implantable cardioverter defibrillators (S-ICDs) has provided invest

246 tification of primary prevention implantable cardioverter defibrillators considering the competing ri

247 Women receiving implantable cardioverter defibrillators for primary prevention of su

248 tients were excluded if they had implantable cardioverter defibrillators or permanent pacemakers.

249 gs implanted with single-chamber implantable cardioverter defibrillators to record ventricular arrhyt

250 Implantable cardioverter defibrillators were common despite numerous

251 Implantable-cardioverter defibrillators were implanted in <0.1%, 4%,

252 Implantable cardioverter defibrillators were placed in 121 (54%) and

253 total of 160 (154 men, 94% with implantable cardioverter defibrillators) consecutive post-myocardial

254 to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients With Non-Ischem

255 hospitals); 2) ICD Registry for implantable cardioverter-defibrillators (158,649 procedures performe

256 Antitachycardia pacing (ATP) in implantable cardioverter-defibrillators (ICD) decreases patient shoc

257 Remote monitoring (RM) of implantable cardioverter-defibrillators (ICD) is an established tech

258 I) of patients with conventional implantable cardioverter-defibrillators (ICD) is contraindicated.

259 patients with primary prevention implantable cardioverter-defibrillators (ICD) may experience an impr

260 Implantable cardioverter-defibrillators (ICDs) are a standard means

261 Older recipients of implantable cardioverter-defibrillators (ICDs) are at increased risk

262 Although implantable cardioverter-defibrillators (ICDs) are frequently viewed

263 Implantable cardioverter-defibrillators (ICDs) are not recommended w

264 sudden cardiac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the mainstay of t

265 stay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often ca

266 te guideline criteria for use of implantable cardioverter-defibrillators (ICDs) do not take into acco

267 The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary preventio

268 Clinical trials of implantable cardioverter-defibrillators (ICDs) for secondary prevent

269 erse HCM complication, including implantable cardioverter-defibrillators (ICDs) for sudden death prev

270 The number of implantable cardioverter-defibrillators (ICDs) for the prevention of

271 Implantable cardioverter-defibrillators (ICDs) have a role in preven

272 Clinical trials of prophylactic implantable cardioverter-defibrillators (ICDs) have included a minor

273 The programming of implantable cardioverter-defibrillators (ICDs) influences inappropri

274 patients with primary prevention implantable cardioverter-defibrillators (ICDs) meet guideline-derive

275 ver, the selection of patients for implanted cardioverter-defibrillators (ICDs), as well as programmi

276 al fibrillation in patients with implantable cardioverter-defibrillators (ICDs), but ventricular proa

277 n management strategy, including implantable cardioverter-defibrillators (ICDs), heart transplantatio

278 ecific, strategic programming of implantable cardioverter-defibrillators (ICDs), including faster det

279 and 2011 with pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), or cardiac resynchro

280 cal trials of primary prevention implantable cardioverter-defibrillators (ICDs).

281 utcomes among patients receiving implantable cardioverter-defibrillators (ICDs).

282 ients undergoing implantation of implantable cardioverter-defibrillators (ICDs); however, whether out

283 ts received secondary prevention implantable cardioverter-defibrillators (long QT syndrome, 9; Brugad

284 Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival i

285 tients (123 pacemakers [57%]; 92 implantable cardioverter-defibrillators [43%]).

286 ers alone in 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%) patients, l

287 propriate use criteria (AUC) for implantable cardioverter-defibrillators and cardiac resynchronizatio

288 Implantable cardioverter-defibrillators are indicated for prevention

289 th dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase longevity.

290 risk patients and utilization of implantable cardioverter-defibrillators for prevention of sudden dea

291 risk patients who benefited from implantable cardioverter-defibrillators for sudden death prevention,

292 ents implanted with subcutaneous implantable cardioverter-defibrillators from 2 hospitals between 200

293 ve cohort study of patients with implantable cardioverter-defibrillators identified from commercial a

294 I [ADVANCE III], and Programming Implantable Cardioverter-Defibrillators in Patients with Primary Pre

295 Implantable cardioverter-defibrillators were placed in 59% of patien

296 s (CIEDs), including pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronizati

297 In patients with implantable cardioverter-defibrillators, healthcare utilization (HCU

298 Device therapy, primarily with implantable cardioverter-defibrillators, is often recommended for pa

299 ourse for CIEDs, pacemakers, and implantable cardioverter-defibrillators, respectively.

300 f approximately 3 to 7 years for implantable cardioverter-defibrillators.